Who are BAY14-2222_Kogenate-FS FVIII's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): ReFacto, rFVIIIFc, Efmoroctocog Alfa Injection [Eloctate], Plasma-derived FVIII/VWF concentrate, OBIZUR, Recombinant Von Willebrand factor.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/bay14-2222-kogenate-fs-fviii.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-18 · How we verify

BAY14-2222_Kogenate-FS FVIII — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

BAY14-2222_Kogenate-FS FVIII (BAY14-2222_Kogenate-FS FVIII) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Factor VIII replacement therapy. Area: Hematology.

phase 2 Factor VIII replacement therapy Factor VIII Hematology Biologic Live · refreshed every 30 min

Target snapshot

BAY14-2222_Kogenate-FS FVIII (BAY14-2222_Kogenate-FS FVIII) — Bayer. Factor VIII replacement therapy

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
BAY14-2222_Kogenate-FS FVIII TARGET	BAY14-2222_Kogenate-FS FVIII	Bayer	phase 2	Factor VIII replacement therapy	Factor VIII
ReFacto	ReFacto	Wyeth is now a wholly owned subsidiary of Pfizer	marketed	Recombinant clotting factor	Factor VIII (antihemophilic factor)
rFVIIIFc	rFVIIIFc	Bioverativ Therapeutics Inc.	marketed	Recombinant clotting factor (Factor VIII replacement therapy)	Factor VIII / FcRn (neonatal Fc receptor)
Efmoroctocog Alfa Injection [Eloctate]	Efmoroctocog Alfa Injection [Eloctate]	The League of Clinical Research, Russia	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII (intrinsic tenase complex)
Plasma-derived FVIII/VWF concentrate	Plasma-derived FVIII/VWF concentrate	Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico	marketed	Coagulation factor concentrate	Factor VIII and von Willebrand Factor
OBIZUR	OBIZUR	Baxalta now part of Shire	marketed	Recombinant coagulation factor VIII	Coagulation factor VIII
Recombinant Von Willebrand factor	Recombinant Von Willebrand factor	Nicoletta C Machin	marketed	Recombinant coagulation factor	Von Willebrand factor receptor (GPIb-IX-V complex on platelets); Factor VIII binding site

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Factor VIII replacement therapy class)

Baxalta now part of Shire · 2 drugs in this class
Bayer · 1 drug in this class
CSL Behring · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). BAY14-2222_Kogenate-FS FVIII — Competitive Intelligence Brief. https://druglandscape.com/ci/bay14-2222-kogenate-fs-fviii. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab